je.st
news
Tag: to
Tesla Q3 deliveries up 70% from Q2 to 24,500 vehicles
2016-10-02 22:55:24| Green Car Congress
Tags: to
vehicles
deliveries
tesla
Reality Check: Does the UK sell boomerangs to Australia?
2016-09-29 18:18:09| BBC News | Business | UK Edition
Has the UK really sold tea to China, wine to France and boomerangs to Australia?
Volkswagen unveils I.D. EV concept; 1st MEB-based vehicle, to launch in 2020; up to 373 miles
2016-09-29 08:55:23| Green Car Congress
Google AI Gives More Context to Chinese-to-English Translations
2016-09-29 00:23:03| TechNewsWorld
Research at Google on Tuesday launched Google Neural Machine Translation system, now in production with Chinese to English -- "a notoriously difficult language pair," according to Quoc V. Le and Mike Schuster, research scientists on the Google Brain Team. GNMT already is powering the Google Translate mobile and Web apps for 18 million or so Chinese to English translations daily.
Tags: to
google
context
translations
Two New Trials of Mercks KEYTRUDA (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016
2016-09-28 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented Comprehensive Data from Mercks Industry-Leading Immuno-Oncology Clinical Development Program to be Presented, with New Data in 12 Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 11. In total, findings from 30 studies in 12 cancers from Mercks industry-leading clinical development program for KEYTRUDA both as monotherapy and in combination will be presented at this years ESMO. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
advanced
presented
cell
Sites : [611] [612] [613] [614] [615] [616] [617] [618] [619] [620] [621] [622] [623] [624] [625] [626] [627] [628] [629] [630] next »